Clinical Trials
79 trialsBevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
National Cancer Institute (NCI)
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Natural Killer Cells and Bortezomib to Treat Cancer
National Institutes of Health Clinical Center (CC)
ASSIST
Massachusetts General Hospital
Edwards EVOQUE Eos MISCEND Study
Edwards Lifesciences
ThINKK-01
St. Justine's Hospital
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
SELECT-CAR-NK
Essen Biotech
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
City of Hope Medical Center
An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer
Memorial Sloan Kettering Cancer Center
A Study of LY3039478 in Participants With Advanced Cancer
Eli Lilly and Company
ON-5001
OncoNano Medicine, Inc.
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
PROBE
Antengene Corporation
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
Cedars-Sinai Medical Center
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
BPGbio
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
Vector Vitale LLC
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
TSN222 in Subjects With Advanced Solid Tumors or Lymphomas
Tyligand Bioscience (Shanghai) Limited
Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients
Cedars-Sinai Medical Center
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
Synlogic
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
Trial of Written Exposure for Metastatic Cancer Patients (EASE)
University of Colorado, Boulder
A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers
Innovent Biologics (Suzhou) Co. Ltd.
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Chinese PLA General Hospital
HLX301
Shanghai Henlius Biotech
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
Memorial Sloan Kettering Cancer Center
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Celgene
CD205SHUTTLE
Menarini Group
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
Northwestern University
An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma
Chinese PLA General Hospital
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Amgen
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
Dalteparin in Preventing DVT in Participants With Cancer
M.D. Anderson Cancer Center
IACS-010759 in Advanced Cancers
M.D. Anderson Cancer Center
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation